About Access Bio
Access Bio is a company based in Somerset (United States) founded in 2001. Access Bio has raised $22 million across 3 funding rounds from investors including Global Health Investment Corporation. The company has 52 employees as of December 31, 2022. Access Bio offers products and services including CareStart COVID-19 Antigen Home Test, CareStart COVID-19 MDx RT-PCR, CareStart Malaria RDT, CareStart Dengue RDT, and CareStart Flu A&B Plus+. Access Bio operates in a competitive market with competitors including SD Biosensor, Lumos Diagnostics, Fluxergy, Module Innovations and DxGen, among others.
- Headquarter Somerset, United States
- Employees 52 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 Shs
-
Annual Revenue
$76.23 M (USD)-67.78as on Dec 31, 2024
-
Net Profit
-$235.61 K (USD)89.06as on Dec 31, 2024
-
EBITDA
$4.09 M (USD)-84.19as on Dec 31, 2024
-
Total Equity Funding
$22 M (USD)
in 3 rounds
-
Latest Funding Round
$10 M (USD), Series A
Nov 20, 2020
- Investors
-
Employee Count
52
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Access Bio
Access Bio is a publicly listed company on the KRX with ticker symbol 950130 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Access Bio
Access Bio offers a comprehensive portfolio of products and services, including CareStart COVID-19 Antigen Home Test, CareStart COVID-19 MDx RT-PCR, CareStart Malaria RDT, CareStart Dengue RDT, and CareStart Flu A&B Plus+.
Rapid antigen test for home-based COVID-19 detection.
RT-PCR kit for accurate COVID-19 virus detection.
Test for quick malaria parasite detection.
Rapid test for dengue virus identification.
Test for influenza A and B virus detection.
Funding Insights of Access Bio
Access Bio has successfully raised a total of $22M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Access Bio
Access Bio has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Global Health Investment Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global health technologies are catalyzed by this nonprofit organization.
|
Locked | Locked | Locked |
Investor details for Access Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Access Bio
Investment portfolio details for Access Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Access Bio
Detailed financials for Access Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Access Bio Comparisons
Peer comparison for Access Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Access Bio
Access Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SD Biosensor, Lumos Diagnostics, Fluxergy, Module Innovations and DxGen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biosensors for point-of-care diagnostics are developed by SD Biosensor.
|
|
| Locked | Locked | Locked |
Diversified diagnostic assays and readers are developed for point-of-care use.
|
|
| Locked | Locked | Locked |
Provides diagnostic devices and software for clinical and veterinary point-of-care testing.
|
|
| Locked | Locked | Locked |
Diagnostics strip for bacterial detection
|
|
| Locked | Locked | Locked |
Point-of-care diagnostic products for diabetes and tuberculosis are provided.
|
Detailed competitors of Access Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Access Bio
Complete news archive for Access Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Access Bio
Access Bio was founded in 2001 and raised its 1st funding round 10 years after it was founded.
Access Bio is headquartered in Somerset, United States.
Access Bio is a funded company, having raised a total of $22M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Access Bio is 52.
Annual revenue of Access Bio is $76.23M as on Dec 31, 2024.
Access Bio was founded in 2001 and is based in Somerset, United States. Operations focus on the medical diagnostics sector, where in vitro rapid tests, biosensors, and molecular diagnostic products are researched, developed, and manufactured for infectious disease detection. Point-of-care tests for malaria, dengue, G6PD deficiency, and pregnancy are provided, along with molecular diagnostics for Congenital Adrenal Hyperplasia and HPV infections.
Access Bio's top competitors include SD Biosensor, Lumos Diagnostics and Module Innovations.
Access Bio offers CareStart COVID-19 Antigen Home Test, CareStart COVID-19 MDx RT-PCR, CareStart Malaria RDT, CareStart Dengue RDT, and CareStart Flu A&B Plus+.
Yes, Access Bio is publicly traded on KRX under the ticker symbol 950130.
Access Bio has 1 investor. Key investors include Global Health Investment Corporation.
The ticker symbol of Access Bio is 950130 on KRX.